Mesothelioma Legal News

The mesothelioma program at University of Chicago Medicine is recruiting patients for its latest clinical trial involving olaparib, an oral chemotherapy drug targeting cancer-driven genetic mutations. This single-center, phase II clinical trial is open to patients with either pleural mesothelioma or peritoneal mesothelioma. Olaparib, also known by the brand name Lynparza, works by repairing or […]

The post Mesothelioma Olaparib Clinical Trial Targets Genetic Mutation appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

The U.S. Social Security Administration has added pericardial mesothelioma to its Compassionate Allowances list, accelerating the disabilities application process for this very rare cancer. Its decision was prompted by the work of Missy Miller, medical outreach director at The Mesothelioma Center. She made the request with the Social Security disability office almost a year ago […]

The post Social Security Adds Pericardial Mesothelioma to Disabilities List appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

A dual registry analysis by the esteemed Duke University Medical Center has concluded that adjuvant hemithoracic radiation does not improve survival when combined with aggressive surgery for patients with malignant pleural mesothelioma. Although the U.S. National Comprehensive Cancer Network and the European Society for Medical Oncology recommend the adjuvant radiation – as do many specialists […]

The post Duke Study Suggests Radiation Does Not Extend Mesothelioma Survival appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

More than half of patients with peritoneal mesothelioma cancer in the United States are being treated at community hospitals, sacrificing the chance to extend survival at an academic/research facility. Too many die sooner than they should. A medical research team at Brigham and Women’s Hospital, a teaching affiliate of Harvard Medical School, has shown that […]

The post Study: Treatment at Academic Facilities Extends Mesothelioma Survival appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

Plaintiff attorneys and congressional leaders have renewed their push against Johnson & Johnson and its allegedly toxic, talc-based powder products, questioning motives and demanding answers, according to various media outlets. A committee of attorneys filed a restraining order in U.S. District Court in Wilmington, Delaware, July 27, hoping to prevent J&J’s potential plan to unload […]

The post J&J Facing Scrutiny from Congress, Black Women’s Organization appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

The U.S. Food and Drug Administration has granted orphan drug designation to ONCOFID-P for the treatment of malignant pleural mesothelioma, a step toward another potential therapy option for patients. ONCOFID-P is an innovative drug conjugate already in advanced clinical development for the treatment of invasive bladder cancer. The mesothelioma designation is based on preclinical data […]

The post FDA Grants Orphan Drug Designation to Novel Mesothelioma Treatment appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

Dr. Maurizio D’Incalci already has seen Tumor Treating Fields working for patients with malignant pleural mesothelioma, and applauded the U.S. Food and Drug Administration’s approval of the treatment in 2019. He also knows the therapy is only scratching the surface of its vast potential and could be even more effective. He wants to help improve […]

The post Researcher Hopes to Improve Tumor Treating Fields for Mesothelioma appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

Memorial Sloan Kettering Cancer Center continues its drive toward a future that may involve innovative CAR T-cell therapy as part of standard-of-care treatment for malignant pleural mesothelioma. The latest step was a clinical trial exploring a first-in-human, intrapleural-administered CAR T-cell therapy used in combination with pembrolizumab, a well-known immunotherapy drug also known by the brand […]

The post CAR T-Cell Therapy Showing Promise with Pleural Mesothelioma appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

Johnson & Johnson is considering the creation of a new subsidiary to absorb its widespread asbestos liabilities, according to reports in The Wall Street Journal and other news outlets. The J&J subsidiary would then declare Chapter 11 bankruptcy, potentially saving the multinational corporation billions of dollars. Reuters News Service also reported the subsidiary possibility, citing […]

The post Johnson & Johnson Weighs Options for Talc Liabilities appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

Researchers at MD Anderson Cancer Center in Houston have uncovered a new, promising treatment option for patients with peritoneal mesothelioma, potentially filling a gaping void that exists today. The immunotherapy drug combination of Tecentriq and Avastin, known generically as atezolizumab and bevacizumab, respectively, showed unusual efficacy in a recent study of 20 patients with this […]

The post New Drug Combination Shows Promise for Peritoneal Mesothelioma appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

A prominent Medicare services collection agency is taking aim at an estimated 60 viable asbestos trust funds, citing a failure to divulge settlement payments and deliver reimbursement to providers for health care services. Asbestos trusts are designed to compensate victims of diseases caused by exposure to asbestos, most notably malignant mesothelioma, a rare cancer with […]

The post Medicare Collection Agency Sets Sights on Asbestos Trusts appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

A phase II study found that treatment with atezolizumab and bevacizumab was well-tolerated and resulted in a 40% objective response rate in patients with advanced malignant peritoneal mesothelioma, a rare cancer in the lining of the abdomen.

It comes as no surprise that immunotherapy is the common theme of the latest batch of the Mesothelioma Applied Research Foundation’s $100,000 grants. Immunotherapy has become the future of cancer care advancements. The foundation, a nonprofit based in Washington, D.C., has provided more than $10.8 million in funding for mesothelioma research in six countries since […]

The post Mesothelioma Research Grants Focus on Immunotherapy appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

A novel, targeted cancer vaccine combined with the immunotherapy drug Opdivo has shown surprising efficacy for mesothelioma patients whose disease no longer responds to standard chemotherapy. In a phase I clinical trial at Memorial Sloan Kettering Cancer Center, the galinpepimut-S vaccine, also known as GPS, has produced an impressive, anti-tumor synergy with Opdivo, based upon […]

The post GPS Vaccine Plus Opdivo Shows Promise for Pleural Mesothelioma appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

Researchers at the much-acclaimed Mayo Clinic in Rochester, Minnesota, have opened the first clinical trial for mesothelioma patients that combines a recently approved immunotherapy treatment with targeted radiation. Potential for extending survival is there. This single-center phase I clinical trial opens June 24, and is expected to enroll at least 20 participants. It will study […]

The post Mayo Clinic Opens Novel Clinical Trial for Mesothelioma appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.